The Interaction Between Heart Failure and Other Heart Diseases, Renal Failure, and Anemia

Seminars in Nephrology

Volumn 26, Issue 4, 2006, Pages 296-306

  Silverberg, Donald S ^a   Wexler, Dov ^a   Iaina, Adrian ^a   Schwartz, Doron ^a  

^a Heart Failure Unit   (Israel)

Author keywords

anemia; erythropoietin; heart failure; iron; renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FUROSEMIDE; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE CORONARY SYNDROME; ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD PRESSURE REGULATION; BONE MARROW; BRAIN CELL; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; CLINICAL TRIAL; COGNITION; COMMUNITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIASTOLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIUM CELL; EXPERIMENTATION; EXTRACELLULAR SPACE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH STATUS; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART SURGERY; HEMATOLOGY; HEMATOPOIETIC SYSTEM; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INTERNAL MEDICINE; INTESTINE ABSORPTION; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON KINETICS; IRON STORAGE; ISCHEMIC HEART DISEASE; KIDNEY CELL; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEDICAL SPECIALIST; MORBIDITY; MORTALITY; NEPHROLOGIST; NONHUMAN; PHYSICIAN ATTITUDE; PLASMA VOLUME; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; STEM CELL; SYSTOLE; UPREGULATION;

ANEMIA; ANIMALS; ATTITUDE; CARDIOLOGY; ERYTHROPOIETIN, RECOMBINANT; HEART DISEASES; HEART FAILURE, CONGESTIVE; HEMOGLOBINS; HUMANS; INTERNAL MEDICINE; IRON; KIDNEY FAILURE, CHRONIC; NATRIURETIC PEPTIDE, BRAIN; NEPHROLOGY;

EID: 33750847474     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.05.006     Document Type: Article

References (118)

1. Van Jaarsveld C.H.M., Ranchor A.V., Kempen G.I.J.M., et al. Etiology of heart failure in a community-based study of subjects aged ≥ 57 years: Incidence and long term survival. Eur J Heart Failure 8 (2006) 23-30
2. Lee D.S., Tu J.V., Juurlink D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 (2005) 1240-1247
3. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
4. Silverberg D.S., Wexler, Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
5. Silverberg D.S., Wexler D., Blum M., et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 21 suppl 3 (2001) S236-S240
6. Silverberg D.S., Wexler D., Blum M., et al. The effect of correction of anemia in diabetic and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
7. Silverberg D.S., Wexler D., Blum M., et al. Effects of treatment with EPO beta on outcomes in patients with anaemia and chronic renal failure. Kidney Blood Press Res 28 (2005) 41-47
8. World Health Organization. Nutritional anemias: Report of a WHO scientific group. WHO Tech Rep Series 405 (1968) 5-37
9. Fonarow G.C., Adams Jr. K.F., Abraham W.T., et al. Risk stratification for in hospital mortality in acutely decompensated heart failure. JAMA 293 (2005) 572-580
10. Packer M., Cohn J.N., et al. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 83 (1999) 1A-38A
11. Hunt S.A., Baker D.W., Chin M.C., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure: Executive summary. J Am Coll Cardiol 38 (2001) 2101-2113
12. Silverberg D.S., Wexler D., Blum M., et al. Erythropoietin should be part of congestive heart failure management. Kidney Int 64 suppl 87 (2003) S40-S47
13. Silverberg D.S., Wexler D., Blum M., et al. The interaction between heart failure, renal failure and anemia-the cardio-renal anemia syndrome. Blood Purif 22 (2004) 277-284
14. Silverberg D.S., Wexler, and Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?. J Nephrol 17 (2004) 749-761
15. Wexler D., Silverberg D.S., Sheps D., et al. Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure. Int J Cardiol 96 (2004) 79-87
16. Silverberg D.S., Wexler D., Blum M., et al. Erythropoietin on heart failure. Semin Nephrol 25 (2005) 397-403
17. Lindenfeld J.A. Prevalence of anemia and the effects on mortality in patients with heart failure. Am Heart J 149 (2005) 391-340
18. Felker G.M., Adams K.F., Gattis W.A., et al. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 44 (2004) 959-966
19. Tang Y.-D., and Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates and treatment options. Circulation 113 (2006) 2454-2461
20. Hunt SA, Abraham WT, Chin MC, et al: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-full text. Available at: http://www.acc.org/clinical/guidelines /failure//index.pdf 1-83
21. Hunt S.A., Abraham W.T., Chin M.C., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. J Am Coll Cardiol 46 (2005) 1116-1143
22. Silverberg D.S., and Wexler D. Anemia, the fifth major cardiovascular risk factor. Transfus Med Hemotherapy 31 (2004) 175-179
23. Anand I., McMurray J.J.V., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110 (2004) 149-154
24. Anand I.S., Kuskowski M.A., Rector T.S., et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure. Circulation 112 (2005) 1121-1127
25. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 12 (2006) 1440-1446 Jun; Epub 2006 May 22 (accessed May 22, 2006)
26. Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45 (2005) 391-399
27. Zuccala G., Marzetti E., Cesari M., et al. Correlates of cognitive impairment among patients with heart failure: Results of a multicenter study. Am J Med 118 (2005) 496-502
28. Shapiro B.P., Chen H.H., Burnett J.C., et al. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc 78 (2003) 481-486
29. Doust J.A., Pietrzak E., Dobson A., et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ 330 (2005) 625-627
30. Takami Y., Horio T., Iwashima Y., et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 44 (2004) 420-428
31. Brucks S., Little W.C., Chao T., et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 93 (2004) 1055-1057
32. Van der Meer P., Voors A.A., Lipsic E., et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44 (2004) 63-67
33. Wu A.H.B., Omland T., Knudsen C.W., et al. Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: A substudy from the Breathing not normal Multinational Study. Am J Hematol 80 (2005) 174-180
34. Ralli S., Horwich T.B., and Fonarow G.C. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and the mortality in patients with advanced heart failure. Am Heart J 150 (2005) 1220-1227
35. Tsuji H., Nishino N., Kimura Y., et al. Haemoglobin level influences plasma brain natriuretic peptide concentration. Acta Cardiol 59 (2004) 527-531
36. Knudsen C.W., Vik-Mo H., and Omland T. Blood hemoglobin is an independent predictor of B-type natriuretic peptide levels. Clin Sci 109 (2005) 69-74
37. Kanka H., Kita Y., Okamura T., et al. What factors are associated with high B-type natriuretic peptide levels in a general Japanese population?. J Hum Hypertens 19 (2005) 165-172
38. Comin-Colet J., Bruguera J., Garcia C., et al. Correction of anemia with subcutaneous erythropoietin and intravenous iron: Effect on NT-pro BNP levels and clinical evolution in patients with severe chronic heart failure and mild renal dysfunction. European J of Heart Failure 41 (2005) (abstr 405, suppl)
39. Palazzuoli A., Iovine F., Capobianco S., et al. The effects of erythropoietin on exercise tolerance, renal function and B-natriuretic peptide in patients with the cardio renal anemia syndrome. Ital Heart J 6 (2005) (abstr, suppl 8)
40. Anand I.S., Chandrashekhar Y., Ferrari R., et al. Pathogenesis of edema in chronic anemia: Studies of body water and sodium, renal function, haemodynamics and plasma hormones. Br Heart J 70 (1993) 357-362
41. Srivistava P.N., Thomas M.C., Calafiore P., et al. Diastolic dysfunction in patients with type 2 diabetes. Clin Sci 110 (2006) 109-116
42. Nair D., Shlipak M.G., Angeja B., et al. Association of anemia with diastolic dysfunction among patients with coronary artery disease in the Heart and Soul Study. Am J Cardiol 95 (2005) 332-336
43. Grigorian Shamagian L., Roman A.V., Acuna J.M.G., et al. Anemia is associated with higher mortality among hospitalized heart failure patients with preserved systolic dysfunction. Heart 26 (2005) 2251-2258
44. Horwich T.B., Fonarow G.C., Hanilton M.A., et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786
45. Laskar S.R., and Dries D.L. The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Curr Cardiol Rep 5 (2003) 205-210
46. Klarenbach S., Stafinski T., Longobardi T., et al. The effect of renal insufficiency on workforce participation in the United States: An analysis using National Health and Nutrition Examination Survey III data. Am J Kidney Dis 40 (2002) 1132-1137
47. Collins A.J., Li S., Gilbertson D.T., et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 64 suppl 87 (2003) S24-S31
48. Avorn J., Bohn R.L., Levy E., et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 162 (2002) 2002-2006
49. Hillege H.L., Girbes A.R.J., de Kam P.J., et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
50. Khan N.A., Ma I., Thompson C.R., et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 17 (2006) 244-253
51. McClellan W.M., Flanders W.D., Langston R.D., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 13 (2002) 1928-1936
52. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure and development and worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
53. Knight E.L., Glynn R.J., McIntyre K.M., et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 38 (1999) 849-855
54. Fine L., Dandyopadhay D., and Norman J.T. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria?. Towards the unifying theme of chronic hypoxia. Kidney Int 57 suppl 75 (2000) S22-S26
55. Sandgren E., Murray A.M., Herzog C.A., et al. Anemia and new-onset congestive heart failure in the general Medicare population. J Card Fail 11 (2005) 99-105
56. Li S., Foley R., and Collins A.J. Anemia and cardiovascular disease, hospitalization, end stage renal disease and death in older patients with chronic kidney disease. Int Urol Nephrol 37 (2005) 395-402
57. Foley R.N., Parfrey P.S., Harnett J.D., et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end stage renal disease. Am J Kidney Dis 28 (1996) 53-61
58. Rigatto C., Parfrey P., Foley R., et al. Congestive heart failure in renal transplant recipients: Risk factors, outcomes and relationship with ischemic heart disease. J Am Soc Nephrol 13 (2002) 1084-1090
59. Rigatto C., Foley R., Jeffrey J., et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14 (2003) 462-468
60. Das S.R., Dries D.L., Drazner M.H., et al. Relationship of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies Of Left Ventricular Dysfunction prevention trial). Am J Cardiol 96 (2005) 827-831
61. Sabatine M.S., Morrow D.A., Giugliano R.P., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111 (2005) 2042-2049
62. Collins A.J. Anaemia management prior to dialysis: Cardiovascular benefits and cost-benefit observations. Nephrol Dial Transplant 18 suppl 2 (2003) ii2-ii6
63. Valderabano F., Horl W., Macdougall I.C., et al. PRE-dialysis survey on anemia management. Nephrol Dial Transplant 18 (2003) 89-100
64. Van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (2005) 125-133
65. Mancini D.M., Katz S.D., Lang C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
66. Androne A.S., Katz S.D., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 107 (2003) 226-229
67. Novak B., Sumodi V., Bynane M., et al. Anemia management in an outpatient heart failure center. J Cardiac Fail 9 (2003) (abstr 386, suppl 1)
68. Delgado R.M., Radovancevic R., van Rossem C.C., et al. Effect of administration of recombinant human erythropoietin in heart failure patients. Eur Heart J 25 suppl 1 (2004) 386A
69. Pappas K., Gouva C., Nikolopoulos P., et al. The beneficial effect of erythropoietin on cardiac function in patients with anaemia and chronic kidney disease. A randomized controlled study. Eur Soc Cardiol Stockholm (2005) (abstr 1773)
70. Cosyns B., and Mantia M. Does the treatment with erythropoietin decrease the left ventricular filling pressure in patients with chronic heart failure?. Eur Soc Cardiol Stockholm (2005) (abstr 1768)
71. Cleland J.G.F., Coletta A.P., Clark A.L., et al. Clinical trial updates from the European Society of Cardiology and the American College of Cardiology. Eur J Heart Failure 7 (2005) 937-939
72. Ghali J.K., Anand I., Abrahan W.T., et al. Randomized double blind placebo controlled trial to assess the impact of darbepoetin alpha treatment on exercise tolerance in patients with symptomatic chronic heart failure and anemia: Results from STAMINA-Heft study. European J of Ht Failure Supplements (2006) (abstr 549, suppl 1)
73. Hampl H., Hennig L., Rosenberger C., et al. Effects of optimized heart failure therapy and anemia correction with epoetin β on left ventricular mass in hemodialysis patients. Am J Nephrol 25 (2005) 211-220
74. Bongartz L.G., Cramer M.J., Doevendans P.A., et al. The severe cardiorenal syndrome: 'Guyton revisited. ' Eur Heart J 26 (2005) 11-17
75. Hunter J.J., and Chien K.R. Signalling pathways for cardiac hypertrophy and failure. N Engl J Med 341 (1999) 1276-1283
76. Anand I.S., Ferrari R., Kalra G.S., et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive heart failure. Circulation 80 (1989) 299-305
77. Anand I.S. Pathogenesis of anemia in cardiorenal syndrome. Rev Cardiovasc Med 6 suppl 3 (2005) S13-S21
78. Herzog C.A., Muster H.A., Li S., et al. Impact of congestive heart failure, chronic kidney disease and anemia on survival in the Medicare population. J Card Fail 10 (2004) 467-472
79. Kuriyama S., Tomonari H., Yoshida H., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron 77 (1997) 176-185
80. Gouva C., Nikolopoulos P., Ioannidis J.P.A., et al. Treating anemia early in renal failure slows the decline of renal function: A randomized controlled study. Kidney Int 66 (2004) 753-760
81. Ershler W.B., Chen K., Reyes E.B., et al. Economic burden of patients with anemia in selected diseases. Value Health 8 (2005) 629-638
82. Nissenson A.R., Wade S., Goodnough T., et al. Economic burden of anemia in an insured population. J Managed Care Pharm 11 (2005) 565-574
83. Nordyke R.J., Kim J.J., Goldberg G.A., et al. Impact of anemia on hospitalization, time, charges, and mortality in patients with heart failure. Value Health 7 (2004) 464-471
84. Gregory D.D., Sarnak M.J., Konstam M.A., et al. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction (Gregory). Am J Cardiol 92 (2005) 1300-1305
85. Wahr J.A. Myocardial ischemia in anaemic patients. Br J Anaesth 81 suppl (1998) 10-15
86. Hebert P.C. Physiological aspects of anemia. Crit Care Clin 20 (2004) 187-212
87. Muntner P., He J., Astor B.C., et al. Traditional and non traditional risk factors predict coronary heart disease: Results from the Atherosclerotic Risk in Communities Study. J Am Soc Nephrol 16 (2005) 529-538
88. Jurkovitz C.T., Abramson J.L., Vaccarino L.V., et al. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 14 (2003) 2919-2925
89. Abramson J.L., Jurkovitz C.T., Vaccarino L.V., et al. Chronic kidney disease, anemia and incident stroke in a middle-aged, community based population: The ARIC Study. Kidney Int 64 (2003) 610-615
90. Leeder S.R., Mitchell P., Liew G., et al. Low hemoglobin, chronic kidney disease and the risk for coronary heart disease-related death: The Blue Mountains Eye Study. J Am Soc Nephrol 17 (2006) 279-284
91. Thomas M.C., MacIsaac R.J., Tsalamandris C., et al. Unrecognized anemia in patients with diabetes. Diabetes Care 26 (2003) 1164-1169
92. Vlagopoulos P.T., Tighiouart H., Weiner D., et al. Anemia a s a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J Am Soc Nephrol 16 (2005) 3403-3410
93. Weiner D.E., Tighiouart H., Vlagopoulos P.T., et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16 (2005) 1803-1810
94. Wu W.-C., Rathore S.S., Wang Y., et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 (2001) 1230-1236
95. Nikolsky E., Aymong E.D., Halkin A., et al. Impact of anemia in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Am Coll Cardiol 44 (2004) 547-553
96. Lipsic E., van der Horst I.C., Voors A.A., et al. Hemoglobin levels and 30 day mortality in patients with myocardial infarction. Int J Cardiol 100 (2005) 289-292
97. Langston R.D., Presley R., Flanders W.D., et al. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int 64 (2003) 1398-1405
98. Arant C.B., Wessel T.R., Olson M.B., et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain. J Am Coll Cardiol 43 (2004) 2009-2014
99. Reinecke H., Trey T., Wellmann J., et al. Hemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 24 (2003) 2142-2150
100. Gurm H.S., Lincoff A.M., Kleiman N.S., et al. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol 94 (2004) 30-34
101. Nikolsky E., Mehran R., Lasic Z., et al. Low hematocrit predicts contrast induced nephropathy after percutaneous coronary interventions. Kidney Int 67 (2005) 706-713
102. Iverson P.O., Woldbaek P.R., Tonnessen T., et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol 282 (2002) R166-R172
103. Herrera-Garza E.H., Stetson S.J., Cubillos-Garzon A., et al. Tumor necrosis factor: A mediator of disease progression in the failing human heart. Chest 115 (1999) 1170-1174
104. Means R.T. Advances in the anemia of chronic disease. Int J Hematol 70 (1999) 7-12
105. Means R.T. Hepcidin and anaemia. Blood Rev 18 (2004) 219-225
106. Deicher R., and Horl W.H. Hepcidin: A molecular link between inflammation and anaemia. Nephrol Dial Transplant 19 (2004) 521-524
107. Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26 (2005) 2232-2237
108. Vaziri N.D. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 38 (2001) 1-8
109. Van der meer P., Lipsic E., Westenbrink D., et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112 (2005) 1743-1747
110. Kooistra M.P., Niemantverdriet E.C., van Es A., et al. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 13 (1998) 82-88
111. Krack A., Sharma R., Figulla H.R., et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26 (2005) 2368-2374
112. van der meer P., Voors A.A., Lipsic E., et al. Erythropoietin in cardiovascular diseases. Eur Heart J 13 (2004) 285-291
113. Maiese K., Li F., and Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 293 (2005) 90-95
114. Tang W.H.W., Miller H., Partin M., et al. Anemia in ambulatory patients with chronic heart failure: A single-center clinical experience derived from electronic medical records. J Am Coll Cardiol 41 suppl A (2003) 157A
115. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12065 patients with new onset heart failure. Circulation 107 (2003) 223-225
116. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. Can J Cardiol 21 (2005) 165-171
117. Kausz A.T., Guo H., Pereira B.J.G., et al. General medical care among patients with chronic kidney disease: Opportunities for improving outcomes. J Am Soc Nephrol 16 (2005) 3092-3101
118. Erdmann E., Lechat P., Verkenne P., et al. Results from post- hoc analyses of the CIBIS II trial: Effect of bisoprolol on high-risk patient groups with chronic heart failure. Eur J Heart Failure 3 (2001) 469-479